Is Jiangsu Recbio Technology (HKG:2179) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how

Simply Wall StJun 5 19:04 ET

Ricoh Bio-B (02179) elects Liu Yong as chairman

Recco Bio-B (02179) issued an announcement. At the annual shareholders' meeting, Dr. Liu Yong, Mr. Li Bu, Chen Qingqing...

Zhitong FinanceMay 8 07:05 ET

Recco Bio-B (02179): Qiao Weiwei and Liu Ping were re-elected as employee representative supervisors

Recco Bio-B (02179) issued an announcement. The company held a staff congress on May 7, 2024. Qiao Wei...

Zhitong FinanceMay 7 06:59 ET

瑞科生物-B：2023年報

Hong Kong Stock ExchangeApr 16 09:59 ET · Announcements

Recco Bio-B (02179) nominated Liu Yong as a candidate for the second board of directors

The term of directors of the second board of directors is three years. It takes effect from the date the relevant bill is reviewed and passed by the company's shareholders' meeting. At the end of their term of office, they can be re-elected.

Zhitong FinanceApr 15 07:32 ET

Recobiotics and Rongsheng Biotech sign a strategic cooperation agreement on a novel adjuvant vaccine project

Taizhou, March 27, 2024/PRNewswire/ -- Recently, Jiangsu Ruike Biotechnology Co., Ltd. (hereinafter referred to as “Recobiology”, stock code: 02179.HK) and Shanghai Rongsheng Biopharmaceutical Co., Ltd. (hereinafter referred to as “Rongsheng Biotech”) successfully held a novel adjuvant vaccine R&D project signing and project launch meeting in Shanghai. At the meeting, the two sides signed a strategic cooperation agreement on the novel adjuvant vaccine project and discussed in depth the details of the project progress. Adjuvants are important components in vaccine development, and novel adjuvants have become the key to the success of innovative vaccine development. According to this section of the agreement

PR NewswireMar 26 23:01 ET